Gilead Sciences (GILD) Stock Price, News & Analysis

Company Overview

Gilead Sciences, Inc. (NASDAQ: GILD) is a biopharmaceutical company headquartered in Foster City, California, specializing in the research, development and commercialization of innovative therapeutics. The company’s core business activities focus on antiviral treatments, with a robust portfolio addressing HIV, viral hepatitis B and C, and more recently COVID-19 through its investigational and approved therapies. Gilead’s leading antiviral products include Biktarvy and Truvada for HIV, Viread for hepatitis B, and Veklury (remdesivir), which received emergency use authorization for COVID-19 treatment.

Since its founding in 1987 by Dr. Michael L. Riordan, Gilead has expanded into oncology and cell therapy, notably advancing CAR-T treatments such as Yescarta for certain blood cancers. The company’s global operations span North America, Europe, Asia and Latin America, supported by research facilities and commercial offices in key markets. Gilead maintains strategic partnerships and licensing agreements to enhance access to its medicines, particularly in low- and middle-income countries.

Under the leadership of President and CEO Daniel O’Day, who joined the company in 2019, Gilead has intensified its focus on pipeline innovation, investing in next-generation antivirals, immuno-oncology and anti-fibrotic therapies. The company’s R&D efforts are centered around translational science and precision medicine, leveraging advanced platforms to identify new molecular targets and accelerate clinical development. Gilead’s commitment to patient access, scientific collaboration and regulatory excellence continues to drive its mission of delivering transformative therapies worldwide.

Key Stats

• Today's Range: $117.07 to $119.07
• 50-Day Range: $110.28 to $120.47
• 52-Week Range: $85.60 to $121.83
• Volume: 4.55 million shs
• Average Volume: 7.87 million shs
• Market Capitalization: $146.79 billion
• P/E Ratio: 23.57
• Dividend Yield: 2.67%
• Price Target: $118.08
• Consensus Rating: Moderate Buy

Gilead Sciences Stock Analysis - MarketRank™

Gilead Sciences scored higher than 98% of companies evaluated by MarketBeat, and ranked 24th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Gilead Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 21 buy ratings, 6 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Gilead Sciences is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Gilead Sciences has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 2.01%

Earnings Growth

Earnings for Gilead Sciences are expected to grow by 2.01% in the coming year, from $7.95 to $8.11 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Gilead Sciences is 23.57, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 233.24.

Price to Earnings Ratio vs. Sector

The P/E ratio of Gilead Sciences is 23.57, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 85.36.

Price to Earnings Growth Ratio

Gilead Sciences has a PEG Ratio of 0.81. PEG Ratios below 1 indicate that a company could be undervalued.

Price to Book Value per Share Ratio

Gilead Sciences has a P/B Ratio of 7.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.47% of the float of Gilead Sciences has been sold short.

Short Interest Ratio / Days to Cover

Gilead Sciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Gilead Sciences has recently increased by 3.93%, indicating that investor sentiment is decreasing.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Yield

Gilead Sciences pays a meaningful dividend of 2.67%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Gilead Sciences has been increasing its dividend for 10 years.

Dividend Coverage

The dividend payout ratio of Gilead Sciences is 62.95%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Gilead Sciences will have a dividend payout ratio of 38.96% next year. This indicates that Gilead Sciences will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -2.24

Percentage of Shares Shorted

1.47% of the float of Gilead Sciences has been sold short.

Short Interest Ratio / Days to Cover

Gilead Sciences has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Gilead Sciences has recently increased by 3.93%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 4.0 / 5
• News Sentiment: 1.16

News Sentiment

Gilead Sciences has a news sentiment score of 1.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 58 news articles for Gilead Sciences this week, compared to 50 articles on an average week.

Search Interest

58 people have searched for GILD on MarketBeat in the last 30 days. This is an increase of 23% compared to the previous 30 days.

MarketBeat Follows

35 people have added Gilead Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 169% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Gilead Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,853,430.00 in company stock.

Percentage Held by Insiders

Only 0.27% of the stock of Gilead Sciences is held by insiders.

Percentage Held by Institutions

83.67% of the stock of Gilead Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GILD Stock Analysis - Frequently Asked Questions

How have GILD shares performed this year?

Gilead Sciences' stock was trading at $92.37 at the start of the year. Since then, GILD shares have increased by 28.1% and is now trading at $118.30.

How were Gilead Sciences' earnings last quarter?

Gilead Sciences, Inc. (NASDAQ:GILD) issued its earnings results on Thursday, August, 7th. The biopharmaceutical company reported $2.01 EPS for the quarter, topping analysts' consensus estimates of $1.96 by $0.05. The firm's revenue was up 1.4% compared to the same quarter last year.
Read the conference call transcript.

Does Gilead Sciences have any subsidiaries?

Gilead Sciences subsidiaries include these companies: MYR, Immunomedics, Forty Seven, Cell Design Labs, Kite Pharma, Nimbus Apollo, Epitherapeutics, and others.

Who are Gilead Sciences' major shareholders?

Gilead Sciences' top institutional investors include Pacer Advisors Inc. (0.29%), Assenagon Asset Management S.A. (0.28%), Swedbank AB (0.20%) and Voya Investment Management LLC (0.17%). Insiders that own company stock include Daniel Patrick O'day, Andrew D Dickinson, Johanna Mercier, Merdad Parsey, Diane E Wilfong and Jeffrey Bluestone.
View institutional ownership trends.

How do I buy shares of Gilead Sciences?

Shares of GILD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Gilead Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gilead Sciences investors own include Cuisine Solutions (CUSI), InnerScope Hearing Technologies (INND), Johnson & Johnson (JNJ), UnitedHealth Group (UNH), Corning (GLW), NextEra Energy (NEE) and American Tower (AMT).

Company Calendar

• Last Earnings: 8/07/2025
• Record date for 9/29 Dividend: 9/15/2025
• Ex-Dividend for 9/29 Dividend: 9/15/2025
• Dividend Payable: 9/29/2025
• Today: 10/15/2025
• Next Earnings (Estimated): 10/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:GILD
• CIK: 882095
• Web: www.gilead.com
• Phone: (650) 574-3000
• Fax: 650-578-9264
• Employees: 17,600
• Year Founded: 1987

Price Target and Rating

• Average Price Target for Gilead Sciences: $118.08
• High Price Target: $145.00
• Low Price Target: $95.00
• Potential Upside/Downside: -0.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.86
• Research Coverage: 29 Analysts

Profitability

• EPS (Trailing Twelve Months): $5.02
• Trailing P/E Ratio: 23.57
• Forward P/E Ratio: 14.88
• P/E Growth: 0.8
• Net Income: $480 million
• Net Margins: 21.86%
• Pretax Margin: 24.95%
• Return on Equity: 50.99%
• Return on Assets: 17.24%

Debt

• Debt-to-Equity Ratio: 1.13
• Current Ratio: 1.32
• Quick Ratio: 1.15

Sales & Book Value

• Annual Sales: $28.75 billion
• Price / Sales: 5.10
• Cash Flow: $6.87 per share
• Price / Cash Flow: 17.21
• Book Value: $15.44 per share
• Price / Book: 7.66

Miscellaneous

• Outstanding Shares: 1,240,810,000
• Free Float: 1,237,457,000
• Market Cap: $146.79 billion
• Optionable: Optionable
• Beta: 0.34